ArticleJournal of neuropathology and experimental neurology2022
The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study.
Article in Journal of neuropathology and experimental neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Curcumin as a potential therapeutic agent for Parkinson's disease: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Celebrating the legacy of two decades of Parkinson's disease research in South Africa.Journal of Parkinson's disease · 2026Article
- Plant-derived therapies in Parkinson's disease: a systematic review of clinical evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Curcumin ameliorates aflatoxin B1-induced brain toxicity in ducks by attenuating inflammation and PANoptosis.Poultry science · 2026Article
- Quantitative measures of total and phosphorylated alpha-synuclein in skin tissue as potential biomarkers for synucleinopathies.Journal of Parkinson's disease · 2026Article
- Interactions Between Nutraceuticals and α-Synuclein Conformational States: Molecular Mechanisms and Neuroprotective Implications in Parkinson's Disease.International journal of molecular sciences · 2026Review
- Therapeutic effects of curcumin on seizure and its mechanisms of action.Inflammopharmacology · 2026Review
- Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint.Molecular neurobiology · 2025Review
- The Neuroprotective Role of Curcumin: From Molecular Pathways to Clinical Translation-A Narrative Review.Nutrients · 2025Review
- Neuroprotective Potential of Curcumin in Neurodegenerative Diseases: Clinical Insights Into Cellular and Molecular Signaling Pathways.Journal of biochemical and molecular toxicology · 2025Review
- Potential therapeutic effects of curcumin, with or without L-DOPA, on motor and cognitive functions and hippocampal changes in rotenone-treated rats.Metabolic brain disease · 2025Article
- Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future.Translational neurodegeneration · 2025Review
- Lead Phytomolecules for Treating Parkinson's Disease.Central nervous system agents in medicinal chemistry · 2025Review
- Bibliometric Analysis of Alpha-Synuclein Determination by Biopsy in Peripheral Tissues of Patients With Parkinson's Disease.International journal of telemedicine and applications · 2025Review
- Diet for the prevention and treatment of Parkinson's disease.Frontiers in nutrition · 2025Review
- The role of neuro-supportive substances of natural origin in neurological conditions-A literature-based formulators' perspective.Frontiers in neurology · 2025Article
- Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies.Frontiers in pharmacology · 2024Review
- The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease.Frontiers in pharmacology · 2024Review
- Nature's weapons: Bioactive compounds as anti-cancer agents.AIMS public health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are currently no standardized therapies for Parkinson disease (PD). Curcumin shows anti-amyloidogenic properties in vitro and may be a promising treatment for PD. We evaluated the effects of curcumin supplementation on clinical scales and misfolded, phosphorylated α-synuclein (p-syn) accumulation in skin biopsies in 19 PD patients who received curcumin supplementation for 12 months and 14 PD patients to treated with curcumin. The patients underwent autonomic (COMPASS-31), motor (MDS-UPDRS and H&Y) and nonmotor (NMSS) questionnaires and skin biopsies to evaluate clinical involvement and p-syn load in skin nerves at the beginning and the end of study. Curcumin and curcuminoid levels were assayed in plasma and CSF. Supplemented patients showed detectable CSF curcuminoid levels that were lower than those in plasma. They showed a decrease of COMPASS-31 and NMSS scores, and a slight p-syn load decrease versus untreated patients who displayed a worsening of these parameters despite increased levodopa doses. Multiple regression models showed a significant effect of curcumin supplementation in decreasing the worsening of the clinical parameters and p-syn load at after curcumin treatment. These data suggest that curcumin can cross the blood-brain barrier, that it is effective in ameliorating clinical parameters and that it shows a tendency to decrease skin p-syn accumulation in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.